Latest big hope against Alzheimer's falls flat in clinical trials

Share this article:
A promising potential treatment for Alzheimer's disease has failed to produce results in the late stages of a clinical trial, according to recent reports.

The drug, Dimebon, had shown immense promise for halting cognitive decline during early testing, according to a report in the New York Times. Originally marketed as an antihistamine in Russia during the 1980s, Dimebon was being developed as an Alzheimer's treatment by San Francisco-based Medivation and global drug giant Pfizer. The results of the first late-stage clinical trial, however, showed that the once-promising drug had virtually no effect after six months of treating mild to moderate Alzheimer's compared with a placebo, the Times reported.

Tests will continue to determine whether Dimebon is effective when coupled with other medications, and the drug is still being tested as a potential treatment for Huntington's disease, the newspaper said. The price of Medivation stock fell by nearly two-thirds to $13.10 Wednesday.


Share this article:

More in News

Bulk of Medicaid to be managed care in two years: Avalere

Bulk of Medicaid to be managed care in ...

More than three-quarters of Medicaid beneficiaries will be enrolled in a managed care plan as of 2016, according to an Avalere Health analysis released Thursday. The numbers reveal that managed ...

Nursing home asked for employee's personal information too often, jury rules

The human resources department of a Maine nursing home did not properly protect a former employee's personal identification information, a jury recently ruled.

Test could confirm sepsis within an hour

Nursing home residents might benefit from a new way of diagnosing and treating sepsis made possible by discoveries out of the University of British Columbia.